(x) di - C_1- C_6- alkylamino, (xi) phenyl wherein the phenyl ring is unsubstituted or substituted with a substituent selected from halo, C_1- C_6- loweralkyl, hydroxy, C_1- C_6- alkoxy , benzyloxy, C_1- C_6- thioalkoxy and benzyl-S-, (xii) phenyl - C_1- C_6- alkyl wherein the phenyl ring is unsubstituted or substituted as defined above, (xiii) di - C_1- C_6- alkylamino - C_1- C_6- alkyl, (xiv) C_1- C_6- alkoxy or benzyloxy and (xv) C_1- C_6- thioalkoxy or benzyl-S-;

E 1 Cont

n is 1, 2 or 3;

R_2 is hydrogen or C_1- C_6- loweralkyl;

R_3 is C_1- C_6- loweralkyl;

R_4 and R_{4a} are independently selected from phenyl and substituted phenyl wherein the phenyl ring is substituted with a substituent selected from (i) halo, (ii) C_1- C_6- loweralkyl, (iii) hydroxy, (iv) C_1- C_6- alkoxy or benzyloxy and (v) C_1- C_6- thioalkoxy or benzyl-S-;

R_6 is hydrogen or C_1- C_6- loweralkyl;

R_7 is thiazolyl or oxazolyl wherein the thiazolyl or oxazolyl ring is unsubstituted or substituted with C_1- C_6- loweralkyl;

X is hydrogen and Y is -OH [or X is -OH and Y is hydrogen, with the proviso that X is hydrogen and Y is -OH when Z is -N(R_8)- and R_7 is unsubstituted and with the proviso that X is hydrogen and Y is -OH when R_3 is methyl and R_7 is unsubstituted] ; and

Z is absent, -O-, -S-, -CH_2- or -N(R_8)- wherein R_8 is C_1- C_6- loweralkyl, C_3- C_7- cycloalkyl, -OH or -NHR_{8a} wherein R_{8a} is hydrogen, C_1- C_6- loweralkyl or an N-protecting group **selected from the group consisting of formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl, α-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, benzenesulfonyl, p-toluenesulfonyl, benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p-biphenylyl)-1-methylethoxycarbonyl, α,α-dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryloxycarbonyl,**

t-butyloxycarbonyl, diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2,-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl, cyclopentyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl, phenylthiocarbonyl, benzyl, triphenylmethyl, benzyloxymethyl and trimethylsilyl ;

or a pharmaceutically acceptable salt thereof .

2. **(four times amended)** A compound of the formula:



wherein R_1 is monosubstituted thiazolyl or monosubstituted oxazolyl wherein the substituent is selected from (i) C_1- C_6- loweralkyl, (ii) C_2- C_6- loweralkenyl, (iii) C_3- C_7- cycloalkyl, (iv) C_3- C_7- cycloalkyl - C_1- C_6- alkyl, (v) C_5- C_7- cycloalkenyl, (vi) C_5- C_7- cycloalkenyl - C_1- C_6- alkyl, (vii) C_1- C_6- alkoxy - C_1- C_6- alkyl or benzyloxy - C_1- C_6- alkyl, (viii) C_1- C_6- thioalkoxy - C_1- C_6- alkyl or benzyl- S - C_1- C_6- alkyl, (ix) C_1- C_6- alkylamino, (x) di - C_1- C_6- alkylamino, (xi) phenyl wherein the phenyl ring is unsubstituted or substituted with a substituent selected from halo, C_1- C_6- loweralkyl, hydroxy, C_1- C_6- alkoxy , benzyloxy, C_1- C_6- thioalkoxy and benzyl-S-, (xii) phenyl - C_1- C_6- alkyl wherein the phenyl ring is unsubstituted or substituted as defined above, (xiii) di - C_1- C_6- alkylamino - C_1- C_6- alkyl, (xiv) C_1- C_6- alkoxy or benzyloxy and (xv) C_1- C_6- thioalkoxy or benzyl-S-;

n is 1 ;

R_2 is hydrogen or C_1- C_6- loweralkyl;

R_3 is C_1- C_6- loweralkyl;

R_4 is phenyl wherein the phenyl ring is unsubstituted or substituted with a substituent selected from (i) halo, (ii) C_1- C_6- loweralkyl, (iii) hydroxy, (iv) C_1- C_6- alkoxy or benzyloxy and (v) C_1- C_6- thioalkoxy or benzyl-S-;

R_5 is hydrogen, halo, C_1- C_6- loweralkyl, hydroxy, C_1- C_6- alkoxy , benzyloxy , C_1- C_6- thioalkoxy or benzyl-S-;

R_6 is hydrogen or C_1- C_6- loweralkyl;

R_7 is thiazolyl or oxazolyl wherein the thiazolyl or oxazolyl ring is unsubstituted or substituted with C_1- C_6- loweralkyl;

E1 Cont

X is hydrogen and Y is -OH ;

Z is absent, -O-, -S-, $-CH_2-$ or $-N(R_8)-$ wherein R_8 is C_1- C_6- loweralkyl, C_3- C_7- cycloalkyl, -OH or $-NHR_{8a}$ wherein R_{8a} is hydrogen [,] **or** C_1- C_6- loweralkyl [or an N-protecting group] ;

or a pharmaceutically acceptable salt thereof .

Please add the following new claims:

33. A compound of the formula:

E2



T1960X

wherein R_1 is monosubstituted thiazolyl or monosubstituted oxazolyl wherein the substituent is selected from (i) C_1- C_6- loweralkyl, (ii) C_2- C_6- loweralkenyl, (iii) C_3- C_7- cycloalkyl, (iv) C_3- C_7- cycloalkyl - C_1- C_6- alkyl, (v) C_5- C_7- cycloalkenyl, (vi) C_5- C_7- cycloalkenyl - C_1- C_6- alkyl, (vii) C_1- C_6- alkoxy - C_1- C_6- alkyl or benzyloxy - C_1- C_6- alkyl, (viii) C_1- C_6- thioalkoxy - C_1- C_6- alkyl or benzyl- S - C_1- C_6- alkyl, (ix) C_1- C_6- alkylamino, (x) di - C_1- C_6- alkylamino, (xi) phenyl wherein the phenyl ring is unsubstituted or substituted with a substituent selected from halo, C_1- C_6- loweralkyl, hydroxy, C_1- C_6- alkoxy , benzyloxy, C_1- C_6- thioalkoxy and benzyl-S-, (xii) phenyl - C_1- C_6- alkyl wherein the phenyl ring is unsubstituted or substituted as defined above, (xiii) di - C_1- C_6- alkylamino - C_1- C_6- alkyl, (xiv) C_1- C_6- alkoxy or benzyloxy and (xv) C_1- C_6- thioalkoxy or benzyl-S-;

n is 1, 2 or 3;

R_2 is hydrogen or C_1- C_6- loweralkyl;

196

R_4 and R_{4a} are independently selected from phenyl and substituted phenyl wherein the phenyl ring is substituted with a substituent selected from
(i) halo, (ii) C_1- C_6- loweralkyl, (iii) hydroxy, (iv) C_1- C_6- alkoxy or benzyloxy and
(v) C_1- C_6- thioalkoxy or benzyl-S-;

E2 Cont

R_6 is hydrogen or C_1- C_6- loweralkyl;

R_7 is thiazolyl or oxazolyl wherein the thiazolyl or oxazolyl ring is unsubstituted and R_3 is C_2- C_6- loweralkyl and Z is absent, -O-, -S- or -CH_2- ;
or
R_7 is thiazolyl or oxazolyl wherein the thiazolyl or oxazolyl ring is substituted with C_1- C_6- loweralkyl and R_3 is C_1- C_6- loweralkyl and Z is absent, -O-, -S-, -CH_2- or -N(R_8)- wherein R_8 is C_1- C_6- loweralkyl, C_3- C_7- cycloalkyl, -OH or -NHR_{8a} wherein R_{8a} is hydrogen, C_1- C_6- loweralkyl or an N-protecting group selected from the group consisting of formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl, α-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, benzenesulfonyl, p-toluenesulfonyl, benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p-biphenylyl)-1-methylethoxycarbonyl, α,α-dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryloxycarbonyl, t-butyloxycarbonyl, diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2,-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl, cyclopentyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl, phenylthiocarbonyl, benzyl, triphenylmethyl, benzyloxymethyl and trimethylsilyl ; and

X is -OH and Y is hydrogen;

or a pharmaceutically acceptable salt thereof .

34. A compound of the formula:



wherein R_1 is monosubstituted thiazolyl or monosubstituted oxazolyl wherein the substituent is selected from (i) C_1- C_6- loweralkyl, (ii) C_2- C_6- loweralkenyl, (iii) C_3- C_7- cycloalkyl, (iv) C_3- C_7- cycloalkyl - C_1- C_6- alkyl, (v) C_5- C_7- cycloalkenyl, (vi) C_5- C_7- cycloalkenyl - C_1- C_6- alkyl, (vii) C_1- C_6- alkoxy - C_1- C_6- alkyl or benzyloxy - C_1- C_6- alkyl, (viii) C_1- C_6- thioalkoxy - C_1- C_6- alkyl or benzyl- S - C_1- C_6- alkyl, (ix) C_1- C_6- alkylamino, (x) di - C_1- C_6- alkylamino, (xi) phenyl wherein the phenyl ring is unsubstituted or substituted with a substituent selected from halo, C_1- C_6- loweralkyl, hydroxy, C_1- C_6- alkoxy , benzyloxy, C_1- C_6- thioalkoxy and benzyl-S-, (xii) phenyl - C_1- C_6- alkyl wherein the phenyl ring is unsubstituted or substituted as defined above, (xiii) di - C_1- C_6- alkylamino - C_1- C_6- alkyl, (xiv) C_1- C_6- alkoxy or benzyloxy and (xv) C_1- C_6- thioalkoxy or benzyl-S-;

n is 1;

R_2 is hydrogen or C_1- C_6- loweralkyl;

R_4 is phenyl or substituted phenyl wherein the phenyl ring is substituted with a substituent selected from (i) halo, (ii) C_1- C_6- loweralkyl, (iii) hydroxy, (iv) C_1- C_6- alkoxy or benzyloxy and (v) C_1- C_6- thioalkoxy or benzyl-S-;

R_6 is hydrogen or C_1- C_6- loweralkyl;

R_7 is thiazolyl or oxazolyl wherein the thiazolyl or oxazolyl ring is unsubstituted and R_3 is C_2- C_6- loweralkyl and Z is absent, -O-, -S- or -CH_2- ;

or

R_7 is thiazolyl or oxazolyl wherein the thiazolyl or oxazolyl ring is substituted with C_1- C_6- loweralkyl and R_3 is C_1- C_6- loweralkyl and Z is absent, -O-, -S-, -CH_2- or -N(R_8)- wherein R_8 is C_1- C_6- loweralkyl, C_3- C_7- cycloalkyl, -OH or -NHR_{8a} wherein R_{8a} is hydrogen or C_1- C_6- loweralkyl; and

X is -OH and Y is hydrogen;

or a pharmaceutically acceptable salt thereof . - -